TScan Therapeutics (TCRX) Debt to Equity (2022 - 2025)
TScan Therapeutics (TCRX) has disclosed Debt to Equity for 4 consecutive years, with $0.26 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity rose 98.53% to $0.26 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.26, a 98.53% increase, with the full-year FY2025 number at $0.26, up 98.53% from a year prior.
- Debt to Equity was $0.26 for Q4 2025 at TScan Therapeutics, up from $0.23 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.38 in Q1 2023 to a low of $0.12 in Q2 2024.
- A 4-year average of $0.21 and a median of $0.19 in 2023 define the central range for Debt to Equity.
- Biggest YoY gain for Debt to Equity was 98.53% in 2025; the steepest drop was 37.76% in 2025.
- TScan Therapeutics' Debt to Equity stood at $0.29 in 2022, then tumbled by 32.39% to $0.2 in 2023, then plummeted by 33.17% to $0.13 in 2024, then surged by 98.53% to $0.26 in 2025.
- Per Business Quant, the three most recent readings for TCRX's Debt to Equity are $0.26 (Q4 2025), $0.23 (Q3 2025), and $0.18 (Q2 2025).